Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns | CNN
Lecanemab, an experimental Alzheimer's drug, shows potential in slowing cognitive decline by 27% in Phase 3 trials, despite safety concerns. It reduces amyloid levels and cognitive decline more than placebo at 18 months but is associated with adverse events like brain swelling and bleeding. Longer trials are needed to confirm its efficacy and safety.
Reference News
Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns | CNN
Lecanemab, an experimental Alzheimer's drug, shows potential in slowing cognitive decline by 27% in Phase 3 trials, despite safety concerns. It reduces amyloid levels and cognitive decline more than placebo at 18 months but is associated with adverse events like brain swelling and bleeding. Longer trials are needed to confirm its efficacy and safety.